Market Place
Sourcing Support
GT20029 China AGA Phase 2 Trial Met Primary Endpoint
21 Apr 2024 //
PR NEWSWIRE
Study of Kintor`s c-Myc Degrader Published in Subsidiary Journal of Nature
13 Mar 2024 //
PR NEWSWIRE
Kintor Pharma Announces the Approval for Phase II Clinical Trial of GT1708F
11 Oct 2023 //
PR NEWSWIRE
Kintor Pharma Announces Completion of Patient Enrollment in PII Trial of GT20029
22 Aug 2023 //
PR NEWSWIRE
Kintor Pharma completes first patient enrollment in PIII trial of KX-826
21 Jul 2023 //
INDIAN PHARMA POST
Kintor succeeds in Phase II study of US males with androgenetic alopecia
12 May 2023 //
CLINICAL TRIALS ARENA
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
30 Mar 2023 //
PR NEWSWIRE
Kintor Announces Completion of Subject Enrollment in Phase III Trial of KX-826
28 Mar 2023 //
PR NEWSWIRE
Kintor`s KX-826 and GT20029 for Treatment of AGA Presented at AAD
21 Mar 2023 //
PR NEWSWIRE
Kintor reports positive data from trial of androgenetic alopecia therapy
13 Feb 2023 //
CLINICAL TRIALS ARENA
Kintor Announced the Primary Endpoint of PII Study for KX-826`s Treatment
01 Dec 2022 //
PRNEWSWIRE
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting
09 Nov 2022 //
PRNEWSWIRE
Kintor Announces Completion of Enrollment and Dosing in PhI Trial of AR-PROTAC
27 Oct 2022 //
PRNEWSWIRE
Kintor Announces Completion of Patient Enrollment in Phase II Trial of KX-826
16 Oct 2022 //
PRNEWSWIRE
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide
29 Sep 2022 //
PRNEWSWIRE
Kintor Announces 2022 Interim Results and Recent Business Update
29 Aug 2022 //
PRNEWSWIRE
Kintor Pharma completes patient enrollment & dosing in phase I trial of GT20029
10 Aug 2022 //
PHARMABIZ
Kintor Pharma Completes Subject Enrollment and Dosing in PI Trial of AR-PROTAC
09 Aug 2022 //
PRNEWSWIRE
Kintor concludes Phase II androgenetic alopecia trial enrolment
04 Aug 2022 //
CLINICALTRIALSARENA
Kintor Pharma Completes Patient Enrollment in Phase II Trial of KX-826
03 Aug 2022 //
PRNEWSWIRE
Kintor Published Results of Study Showing Pruxelutamide`s Inhibitory Effects
16 Jul 2022 //
PRNEWSWIRE
Kintor Pharma and Etana`s Collaboration on Pruxelutamide`s COVID-19 Project
14 Jun 2022 //
ASIAONE
Kintor Pharma Included in MSCI China Index
15 May 2022 //
PRNEWSWIRE
Kintor`s Proxalutamide Showed Reduction in Hospitalization/Mortality in COVID-19
05 Apr 2022 //
PRNEWSWIRE
Kintor Pharma Announces Two Upcoming Poster Presentations at AACR 2022
03 Apr 2022 //
PRNEWSWIRE
Kintor Pharma Announces 2021 Business Progress and Annual Results
25 Mar 2022 //
PRNEWSWIRE
Kintor Pharma Completes Patient Enrollment in Phase II Trial of KX-826
06 Mar 2022 //
PRNEWSWIRE
Kintor Pharma Announces First Patient Dosing in Phase II Trial of KX-826
01 Mar 2022 //
PRNEWSWIRE
Kintor doses first subject in Phase III Covid-19 therapy trial in China
14 Feb 2022 //
CLINICALTRIALSARENA
Kintor Pharma Begins Dosing in Phase III Clinical Trial of Proxalutamide
11 Feb 2022 //
PRNEWSWIRE
Kintor Pharma Begins Dosing in US Phase I Clinical Trial of GT20029
03 Feb 2022 //
PRNEWSWIRE
Kintor Pharma Doses First Patient for Acne Vulgaris Phase II Trial of KX-826
24 Jan 2022 //
PRNEWSWIRE
Kintor Pharma Begins Dosing in Phase III Trial of KX-826 for AGA in China
02 Jan 2022 //
PRNEWSWIRE
Kintor`s interim analysis of COVID treatment trial misses statistical criteria
28 Dec 2021 //
REUTERS
NMPA Clears Kintor`s IND for KX-826`s Pivotal Study in Male Alopecia
24 Nov 2021 //
PRNEWSWIRE
Kintor Pharma begins Phase II trial of KX-826 for androgenetic alopeciatreatment
13 Nov 2021 //
PHARMAFILE
Kintor Pharma begins Phase II trial of KX-826 for androgenetic alopecia
12 Nov 2021 //
PHARMAFILE
Kintor Pharma Announces PD-L1/TGF-? dual-targeting antibody (GT90008)
21 Oct 2021 //
PRNEWSWIRE
Kintor Pharma Announces China NMPA Approves Trial of ALK-1 and Nivolumab
11 Oct 2021 //
PRNEWSWIRE
Kintor begins Phase III trial of proxalutamide for COVID patients in US
05 Oct 2021 //
PHARMAFILE
Kintor begins patient dosing in phase 3 of proxalutamide for Covid-19 patients
05 Oct 2021 //
PHARMABIZ
Kintor begins patient dosing in phase 3 of proxalutamide for Covid-19 patients
05 Oct 2021 //
PHARMABIZ
Kintor Pharma Begins Patient Dosing in Phase III Trial of Proxalutamide
04 Oct 2021 //
PRNEWSWIRE
Kintor receives approval for Covid-19 trial of proxalutamide in Brazil
27 Sep 2021 //
CLINICALTRIALSARENA
Kintor Pharma Announces Brazil approved Proxalutamide
26 Sep 2021 //
PRNEWSWIRE
Kintor Pharma Announces the Primary Endpoint of PhII Clinical Study for KX-826`
08 Sep 2021 //
BIOSPACE
Inclusion of Kintor as a Constituent Stock of HSCI
22 Aug 2021 //
PRNEWSWIRE
Kintor Pharma Dosing First Batch Subjects Clinical Trial of GT20029 in China
28 Jul 2021 //
PRNEWSWIRE
Kintor Pharmaceutical Receives EUA for Proxalutamide
16 Jul 2021 //
PR NEWSWIRE
Kintor Collaborates with Fosun Pharma to Commercialise Proxalutamide
14 Jul 2021 //
PRNEWSWIRE
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029
14 Jul 2021 //
PRNEWSWIRE
Kintor Collaborates with Fosun Pharma to Commercialise Proxalutamide
14 Jul 2021 //
PRNEWSWIRE
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029
14 Jul 2021 //
PRNEWSWIRE
Kintor receives US FDA permission to begin phase II trial of pyrilutamide
13 Jul 2021 //
PHARMABIZ
Kintor receives US FDA permission to begin phase II trial of pyrilutamide
13 Jul 2021 //
PHARMABIZ
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029
13 Jul 2021 //
PRNEWSWIRE
Kintor receives US FDA permission to begin phase II trial of pyrilutamide
12 Jul 2021 //
PHARMABIZ
Kintor Announced FDA Has Greenlighted Pyrilutamide`s Phase II Clinical Trial
12 Jul 2021 //
PRNEWSWIRE
Kintor Announced FDA Has Greenlighted Pyrilutamide`s Phase II Clinical Trial
11 Jul 2021 //
PRNEWSWIRE
Kintor Announced FDA nod for Proxalutamide`s Phase III Study
20 May 2021 //
PRNEWSWIRE
